BidaskClub lowered shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a buy rating to a hold rating in a research report sent to investors on Tuesday.
A number of other research firms have also recently commented on GWPH. Zacks Investment Research cut shares of GW Pharmaceuticals PLC- from a hold rating to a sell rating in a research report on Tuesday. Bank of America decreased their target price on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a buy rating on the stock in a research report on Tuesday, November 14th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $208.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. Cowen reaffirmed an outperform rating and issued a $165.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. Finally, Goldman Sachs Group raised shares of GW Pharmaceuticals PLC- from a neutral rating to a buy rating and set a $174.00 target price on the stock in a research report on Thursday, December 14th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $148.78.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded down $0.56 during midday trading on Tuesday, reaching $131.97. 189,050 shares of the company’s stock were exchanged, compared to its average volume of 428,093. GW Pharmaceuticals PLC- has a 52 week low of $92.65 and a 52 week high of $140.52. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.59 and a quick ratio of 7.47. The firm has a market capitalization of $3,350.00, a PE ratio of -18.72 and a beta of 2.65.
COPYRIGHT VIOLATION WARNING: “BidaskClub Lowers GW Pharmaceuticals PLC- (GWPH) to Hold” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2018/01/13/bidaskclub-lowers-gw-pharmaceuticals-plc-gwph-to-hold.html.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.